{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:14:51Z","timestamp":1794870891446,"version":"4.9.1"},"reference-count":35,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Daiichi Sankyo, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2026,5,15]]},"DOI":"10.1080\/14796694.2026.2663956","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T17:34:35Z","timestamp":1778952875000},"page":"1387-1396","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["TROPION-Urothelial03: a phase II\/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-9378","authenticated-orcid":false,"given":"Matthew D.","family":"Galsky","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8865-3548","authenticated-orcid":false,"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[{"name":"UCLA Health","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-3880","authenticated-orcid":false,"given":"Arnab","family":"Basu","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Jacksonville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8298-0289","authenticated-orcid":false,"given":"Bradley","family":"McGregor","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Harvard Cancer Center","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2778-3108","authenticated-orcid":false,"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[{"name":"Eva Mayr-Stihl Cancer Center","place":["Klinikum Stuttgart, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1739","authenticated-orcid":false,"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[{"name":"Gustave Roussy Cancer Institute","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-6676","authenticated-orcid":false,"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"St. Marianna University School of Medicine","place":["Kawasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital and Research Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-6235","authenticated-orcid":false,"given":"Benjamin","family":"Garmezy","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-1285","authenticated-orcid":false,"given":"Srikala S.","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[{"name":"Mayo Clinic Arizona","place":["Phoenix, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[{"name":"University of California San Francisco, Helen Diller Family Comprehensive Cancer","place":["San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fleming","sequence":"additional","affiliation":[{"name":"Brock Cancer Center","place":["Norfolk, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Klauss","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc","place":["Basking Ridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Lin","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc","place":["Basking Ridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Liu","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc","place":["Basking Ridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9409-1836","authenticated-orcid":false,"given":"Andrea B.","family":"Apolo","sequence":"additional","affiliation":[{"name":"National Cancer Institute","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7760-4724","authenticated-orcid":false,"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[{"name":"Queen Mary University of London","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"e_1_3_7_3_1","unstructured":"World cancer research fund. Worldwide Cancer Data; 2022. [cited 2025 Oct 22]. Available from: https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/worldwide-cancer-data\/#global-cancer-incidence-both-sexes"},{"key":"e_1_3_7_4_1","unstructured":"World cancer research fund. Bladder Cancer Statistics; 2022. [cited 2025 Oct 22]. Available from: https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/bladder-cancer-statistics\/"},{"key":"e_1_3_7_5_1","unstructured":"World Health Organization. Global cancer observatory: bladder. [cited 2025 Nov 20]. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/30-bladder-fact-sheet.pdf"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70019"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.8946"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00167"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_3_7_11_1","unstructured":"MERCK. European commission approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) plus PADCEV\u00ae (enfortumab vedotin-ejfv) as first-line treatment of unresectable or metastatic urothelial carcinoma in adults. [cited 2025 Dec 1]. Available from: https:\/\/www.merck.com\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-first-line-treatment-of-unresectable-or-metastatic-urothelial-carcinoma-in-ad\/"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1393"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2025.1002307"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.06.013"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011881"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01131-0"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0024"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4573"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.785"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061744"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.11.005"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0188"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0206"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-25-0057"},{"key":"e_1_3_7_29_1","unstructured":"DATROWAY\u00ae (datopotamab deruxtecan-dlnk) prescribing information. [cited 2025 Nov 25]. Available from: https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Datroway&inline=true"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1388"},{"key":"e_1_3_7_31_1","unstructured":"European Medicines Agency. Datroway. Summary of product characteristics. [cited 2026 Jan 15]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/datroway-epar-product-information_en.pdf"},{"key":"e_1_3_7_32_1","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. [cited 2025 Dec 1]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.663"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01909"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00059"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.3686"},{"issue":"2","key":"e_1_3_7_37_1","first-page":"Abstract 8O","article-title":"First\u2011line datopotamab deruxtecan + durvalumab \u00b1 carboplatin in advanced or metastatic non\u2011small cell lung cancer: results from TROPION\u2011Lung04 (cohorts 2 and 4)","volume":"10","author":"Cuppens K","year":"2025","unstructured":"Cuppens K, Papadopoulos KP, Nishio M, et al. First\u2011line datopotamab deruxtecan + durvalumab \u00b1 carboplatin in advanced or metastatic non\u2011small cell lung cancer: results from TROPION\u2011Lung04 (cohorts 2 and 4). ESMO Open. 2025;10(suppl 2):Abstract 8O.","journal-title":"ESMO Open"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2663956","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2026.2663956","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2026.2663956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:27:55Z","timestamp":1790576875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2026.2663956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,5,15]]}},"alternative-id":["10.1080\/14796694.2026.2663956"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2026.2663956","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}